Review of Treatment for Adenosine Deaminase Deficiency (ADA) Severe Combined Immunodeficiency (SCID)

References

• Hershfield M. Adenosine deaminase deficiency. In: Pagon RA, Adam MP, Ardinger HH, et al. editors. Genereviews(R). Seattle: University of Washington, Seattle, University of Washington, Seattle: GeneReviews is a registered trademark of the University of Washington, Seattle; 1993. All rights reserved.
   Google Scholar
• Hirschhorn R, Martinuk F, Rosen FS. Adenosine deaminase activity in normal tissues and tissues from a child with severe combined immunodeficiency and adenosine deaminase deficiency. Clin Immunol Immunopathol. 1978;9(3):287–292. doi:10.1016/0090-1229(78)90100-9
   PubMedGoogle Scholar
• Albuquerque W, Gaspar HB. Bilateral sensorineural Hearing deafness in siblings with adenosine deaminase- deficient Severe Combined Immunodeficiency. J Pediatr. 2004;144(2):278–280. doi:10.1016/j.jpeds.2003.10.055
   PubMed Web of Science ®Google Scholar
• Flinn AS, Gennery AR. Adenosine deaminase deficiency: a review. Orphanet J Rare Dis. 2018;13:65–73. doi:10.1186/s13023-018-0807-5
   PubMed Web of Science ®Google Scholar
• Hershfield MS, Buckley RH, Greenberg ML, et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med. 1987;316:589–596. doi:10.1056/NEJM198703053161005
   PubMed Web of Science ®Google Scholar
• Kawash BM, Yonkof JR, Abraham RS, et al. Delayed-onset ADA1 deficiency not detected by TREC screen. Pediatrics. 2021;147(6):33975924. doi:10.1542/peds.2020-005579
   Web of Science ®Google Scholar
• Giblett ER, Anderson JE, Cohen F, Pollara BP, Meuwissen HJ. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet. 1972;300(7786):1067–1069. doi:10.1016/S0140-6736(72)92345-8
   Google Scholar
• Polmar SH, Wetzler EM, Stern RC, Hirschhorn R. Restoration of in-vitro lymphocyte responses with exogenous adenosine deaminase in a patient with severe combined immunodeficiency. Lancet. 1975;306(7938):743–746. doi:10.1016/S0140-6736(75)90726-6
   Google Scholar
• Polmar SH, Stern RC, Schwartz AL, Wetzler EM, Chase PA, Hirschhorn R. Enzyme replacement therapy for adenosine deaminase deficiency and severe combined immunodeficiency. N Engl J Med. 1976;295(24):1337–1343. doi:10.1056/NEJM197612092952402
   PubMed Web of Science ®Google Scholar
• Buckley RH. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol. 2004;22:625–655. doi:10.1146/annurev.immunol.22.012703.104614
   PubMed Web of Science ®Google Scholar
• Chan K, Puck JM. Development of population-based newborn screening for severe combined immunodeficiency. J Allergy Clin Immunol. 2005;115:391–398. doi:10.1016/j.jaci.2004.10.012
   PubMed Web of Science ®Google Scholar
• Kwan A, Abraham RS, Currier R, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312:729–738. doi:10.1001/jama.2014.9132
   PubMed Web of Science ®Google Scholar
• Puck JM. Neonatal screening for severe combined immunodeficiency. Curr Opin Pediatr. 2011;23(6):667–673. doi:10.1097/MOP.0b013e32834cb9b0
   PubMed Web of Science ®Google Scholar
• Buckley RH, Schiff SE, Schiff RI, et al. Hematopoietic stem cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med. 1999;340:508–516. doi:10.1056/NEJM199902183400703
   PubMed Web of Science ®Google Scholar
• Buckley RH. Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: longterm outcomes. Immunol Res. 2011;49:25–43. doi:10.1007/s12026-010-8191-9
   PubMed Web of Science ®Google Scholar
• Kane L, Gennery AR, Crooks BN, Flood TJ, Abinun M, Cant AJ. Neonatal bone marrow transplantation for severe combined immunodeficiency. Arch Dis Child Fetal Neonatal. 2001;85(2):F110–F113. doi:10.1136/fn.85.2.F110
   PubMed Web of Science ®Google Scholar
• Myers LA, Patel DD, Puck JM, Buckley RH. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. Blood. 2002;99(3):872–878. doi:10.1182/blood.V99.3.872
   PubMed Web of Science ®Google Scholar
• Taki M, Miah T, Secord E. Newborn screening for severe combined immunodeficiency. Pediatr Clin North Amer. 2019;66(5):913–923. doi:10.1016/j.pcl.2019.06.007
   PubMed Web of Science ®Google Scholar
• Grazioli S, Bennett M, Hildebrand KJ, Vallance H, Turvey SE, Junker AK. Limitation of TREC-based newborn screening for ZAP70 severe combined immune deficiency. Clin Immunol. 2014;153:209–210. doi:10.1016/j.clim.2014.04.015
   PubMed Web of Science ®Google Scholar
• Azzari C, La marca G, Resti M. Neonatal screening for severe combined immunodeficiency caused by an adenosine deaminase defect: a reliable and inexpensive method using tandem mass spectrometry. J Allergy Clin Immunol. 2011;127:1394–1399. doi:10.1016/j.jaci.2011.03.040
   PubMed Web of Science ®Google Scholar
• Giancarlo LM, Giocaliere E, Malvagia S, et al. The inclusion of ADA-SCID in expanded newborn screening by mass spectrometry. J Pharm Biomed Anal. 2014;88:201–206. doi:10.1016/j.jpba.2013.08.044
   PubMed Web of Science ®Google Scholar
• Bradford K, Moretti FA, Carbonaro-Sarracino DA, Gaspar H, Kohn DB. Adenosine deaminase (ADA)- deficient severe combined immune deficiency (SCID): molecular pathogenesis and clinical manifestations. J Clin Immunol. 2017;37(7):626–637. doi:10.1007/s10875-017-0433-3
   PubMed Web of Science ®Google Scholar
• Kohn DB, Gaspar HB. How we manage adenosine deaminase-deficient severe combined immune deficiency (ADA SCID). J Clin Immunol. 2017;37:351–356. doi:10.1007/s10875-017-0373-y
   PubMed Web of Science ®Google Scholar
• Hassan A, Booth C, Brightwell A, et al. Outcome of hematopoietic stem cell transplantation for adenosine deaminase-deficient severe combined immunodeficiency. Blood. 2012;120(17):3615–3624. doi:10.1182/blood-2011-12-396879
   PubMed Web of Science ®Google Scholar
• Cuvelier GDE, Logan BR, Prockop S, et al. Outcomes following treatment for adenosine deaminase deficient severe combined immunodeficiency: a report from the PIDTC. Blood. 2022;140:685–705. doi:10.1182/blood.2022016196
   PubMed Web of Science ®Google Scholar
• Ferrari G, Rossini S, Giavazzi R, et al. An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency. Science. 1991;251:1363–1366. doi:10.1126/science.1848369
   PubMed Web of Science ®Google Scholar
• Muul LM, Tuschong LM, Soenen SL, et al. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood. 2003;101:2563–2569. doi:10.1182/blood-2002-09-2800
   PubMed Web of Science ®Google Scholar
• Bordignon C, Notarangelo LD, Nobili N, et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science. 1995;270:470–475. doi:10.1126/science.270.5235.470
   PubMed Web of Science ®Google Scholar
• Bordignon C, Mavilio F, Ferrari G, et al. Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID. Hum Gene Ther. 1993;4:513–520. doi:10.1089/hum.1993.4.4-513
   PubMed Web of Science ®Google Scholar
• Kohn DB, Weinberg KI, Nolta JA, et al. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med. 1995;1:1017–1023. doi:10.1038/nm1095-1017
   PubMed Web of Science ®Google Scholar
• Kohn DB, Hershfield MS, Carbonaro D, et al. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat Med. 1998;4:775–780. doi:10.1038/nm0798-775
   PubMed Web of Science ®Google Scholar
• Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296:2410–2413. doi:10.1126/science.1070104
   PubMed Web of Science ®Google Scholar
• Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009;360:447–458. doi:10.1056/NEJMoa0805817
   PubMed Web of Science ®Google Scholar
• Cicalese MP, Ferrua F, Castagnaro L, et al. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. Blood. 2016;128:45–54. doi:10.1182/blood-2016-01-688226
   PubMed Web of Science ®Google Scholar
• Gaspar HB, Bjorkegren E, Parsley K, et al. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol Ther. 2006;14:505–513. doi:10.1016/j.ymthe.2006.06.007
   PubMed Web of Science ®Google Scholar
• Gaspar HB, Cooray S, Gilmour KC, et al. Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci Transl Med. 2011;3:97ra80. doi:10.1126/scitranslmed.3002716
   PubMed Web of Science ®Google Scholar
• Candotti F, Shaw KL, Muul L, et al. Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood. 2012;120:3635–3646. doi:10.1182/blood-2012-02-400937
   PubMed Web of Science ®Google Scholar
• Otsu M, Yamada M, Nakajima S, et al. Outcomes in two Japanese adenosine deaminase-deficiency patients treated by stem cell gene therapy with no cytoreductive conditioning. J Clin Immunol. 2015;35:384–398. doi:10.1007/s10875-015-0157-1
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Strimvelis: First Case of Lymphoid T-Cell Leukaemia After Insertional Oncogenesis. Vol. 2022. European Medicines Agency; 2021.
   Google Scholar
• Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002;346:1185–1193. doi:10.1056/NEJMoa012616
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003;348:255–256. doi:10.1056/NEJM200301163480314
   PubMed Web of Science ®Google Scholar
• Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol. 1998;72:9873–9880. doi:10.1128/JVI.72.12.9873-9880.1998
   PubMed Web of Science ®Google Scholar
• Naldini L. Ex vivo gene transfer and correction for cell-based therapies. Nat Rev. 2011;12:301–315. doi:10.1038/nrg2985
   Google Scholar
• Gaspar HB, Buckland K, Rivat C, et al. Immunological and metabolic correction after lentiviral vector mediated haematopoietic stem cell gene therapy for ADA deficiency. Mol Ther. 2014;22:S106. doi:10.1016/S1525-0016(16)35289-3
   Web of Science ®Google Scholar
• Kohn DB, Booth C, Shaw KL, et al. Autologous ex vivo lentiviral gene therapy for adenosine deaminase deficiency. N Engl J Med. 2021;384:2002–2013. doi:10.1056/NEJMoa2027675
   PubMed Web of Science ®Google Scholar